A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Intravenous Doses Of Pf-05231023 In Adult Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2016
At a glance
- Drugs PF 5231023 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 16 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 16 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.